Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 11 articles:
HTML format



Single Articles


    February 2025
  1. MUSTO P, Engelhardt M, van de Donk NWCJ, Gay F, et al
    European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia.
    Ann Oncol. 2025 Feb 7:S0923-7534(25)00058-4. doi: 10.1016/j.annonc.2025.
    PubMed     Abstract available


    September 2024
  2. EICHHORST B, Ghia P, Niemann CU, Kater AP, et al
    ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.
    Ann Oncol. 2024;35:762-768.
    PubMed    


    January 2024
  3. HOELZER D, Bassan R, Boissel N, Roddie C, et al
    ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia.
    Ann Oncol. 2024;35:15-28.
    PubMed    


    July 2023
  4. CASS SH, Tobin JWD, Seo YD, Gener-Ricos G, et al
    Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma in Patients with Concomitant Chronic Lymphocytic Leukemia.
    Ann Oncol. 2023 Jul 4:S0923-7534(23)00735-4. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available


    January 2023
  5. MALVEZZI M, Santucci C, Boffetta P, Collatuzzo G, et al
    EUROPEAN CANCER MORTALITY PREDICTIONS FOR THE YEAR 2023 WITH FOCUS ON LUNG CANCER.
    Ann Oncol. 2023 Jan 27:S0923-7534(23)00048-0. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available


    November 2022
  6. BAZINET A, Kantarjian HM
    Moving towards individualized target-based therapies in acute myeloid leukemia.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04734-2. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available


    April 2022
  7. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    PubMed    


    March 2022
  8. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    PubMed    


    November 2021
  9. VAN GELDER M, Tournilhac O, Te Raa D, Visser HPJ, et al
    Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL.
    Ann Oncol. 2021;32:1442-1443.
    PubMed    


    August 2021
  10. LORIOT Y, Marabelle A, Guegan JP, Danlos FX, et al
    Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance.
    Ann Oncol. 2021 Aug 17. pii: S0923-7534(21)03978.
    PubMed     Abstract available


    May 2021
  11. DONNETTE M, Ciccolini J, Pissier C, Costello R, et al
    High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications.
    Ann Oncol. 2021;32:684-686.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.